Medical College of Wisconsin
CTSICores SearchResearch InformaticsREDCap

Identification and utilization of donor and recipient genetic variants to predict survival after HCT: are we ready for primetime? Curr Hematol Malig Rep 2015 Mar;10(1):45-58

Date

02/24/2015

Pubmed ID

25700678

Pubmed Central ID

PMC4352187

DOI

10.1007/s11899-014-0246-x

Scopus ID

2-s2.0-84925534523   10 Citations

Abstract

Overall survival following hematopoietic cell transplantation (HCT) has improved over the past two decades through better patient selection and advances in HLA typing, supportive care, and infection prophylaxis. Nonetheless, mortality rates are still unsatisfactory and transplant-related mortality remains a major cause of death after unrelated allogeneic HCT. Since there are no known pre-HCT, non-HLA biologic predictors of survival following transplant, for over a decade, scientists have been investigating the role of non-HLA germline genetic variation in survival and treatment-related mortality after HCT. Variation in single nucleotide polymorphisms (SNPs) has the potential to impact chemotherapy, radiation, and immune responses, leading to different post-HCT survival outcomes. In this paper, we address the current knowledge of the contribution of genetic variation to survival following HCT and discuss study design and methodology for investigating HCT survival on a genomic scale.

Author List

Sucheston-Campbell LE, Clay A, McCarthy PL, Zhu Q, Preus L, Pasquini M, Onel K, Hahn T

Author

Marcelo C. Pasquini MD, MS Professor in the Medicine department at Medical College of Wisconsin




MESH terms used to index this publication - Major topics in bold

Genetic Variation
Graft vs Host Disease
HLA Antigens
Hematologic Neoplasms
Hematopoietic Stem Cell Transplantation
Histocompatibility Testing
Humans
Polymorphism, Single Nucleotide
Receptors, KIR
Survival Rate
Tissue Donors
Transplant Recipients
Transplantation, Homologous
jenkins-FCD Prod-482 91ad8a360b6da540234915ea01ff80e38bfdb40a